Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a Next Day Disclosure Return stating that it repurchased 21,500 H-shares on 15 April 2026 via on-market transactions on the Hong Kong Stock Exchange.

Key transaction metrics • Volume: 21,500 shares • Price range: HKD 28.20–29.80 • Volume-weighted average price: HKD 28.8314 • Total consideration: HKD 0.62 million

Capital structure impact • Issued shares (excluding treasury shares) decreased from 136.04 million to 136.02 million, a reduction of 0.016%. • Treasury shares increased from 179,300 to 200,800. • Total issued shares remained unchanged at 136.22 million, as the repurchased shares are held in treasury and not yet cancelled.

Repurchase mandate utilisation • The repurchase was executed under a mandate approved on 12 February 2026 authorising up to 13.62 million shares. • Cumulative purchases under the mandate now total 200,800 shares, representing 0.1474% of the shares outstanding on the mandate date. • In accordance with listing rules, Hanx Biopharmaceuticals is subject to a 30-day moratorium on issuing, selling or transferring shares until 15 May 2026.

All transactions were confirmed by the board as compliant with the Main Board Listing Rules, relevant laws and regulatory requirements.